Ulixertinib

优立替尼

Report date: 2026/02/26 20:00:22
NME

Base Information

Drug NameUlixertinib
Drug Alias NameUlixertinibum乌利替尼VRT-0752271VRT-752271BVD-ERK/ST +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionExtracellular-signal-regulated kinase1 inhibitorsExtracellular-signal-regulated kinase 2 inhibitors
TargetsExtracellular-signal-regulated kinase1Extracellular-signal-regulated kinase 2
Therapy Area/IndicationsUveal melanomaSolid tumoursMyelodysplastic Syndromes +[27] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPuerto Rico
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesVertex Pharmaceuticals Incorporated
China Registration ClassN/A

Develop Information

Active CompaniesUtah State UniversityBiomed Valley Discoveries IncNational Cancer Institute +[4] 
Inactive CompaniesDana-Farber Cancer InstituteWashington University School Of Medicine
Active IndicationsSolid tumoursHistiocytosis, Langerhans-CellCentral Nervous System Neoplasms +[23] 
Inactive IndicationsUveal melanomaMyelodysplastic SyndromesLeukemia, Myeloid, Acute +[4] 

Other Information

ATC CodeN/A
Related LinksDrugBank